Title : Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma.

Pub. Date : 2018 Oct

PMID : 30065099






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Because the PI3K/AKT/mTOR pathway is one of the major downstream pathways of EGFR, we hypothesized that ibrutinib"s activity might be enhanced by combination therapy with auranofin in NSCLC cells. ibrutinib AKT serine/threonine kinase 1 Homo sapiens
2 The combination of ibrutinib and auranofin led to a dramatically enhanced inhibition of the expression or phosphorylation of multiple key nodes in the AKT/mTOR and MEK/ERK pathways in both cell lines. ibrutinib AKT serine/threonine kinase 1 Homo sapiens